An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Condition: Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Intervention: Drug: Dacomitinib Sponsor: Guangdong Association of Clinical Trials Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Research | Study